Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 12/20 | 0.47 |
| ▸ | BTK | Q06187 | 4/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | RHOA | P61586 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024611 | 1.00 | MEN1 (0.49) | MEN1NPC1RAB9AKMT2AEGFR | |
| SCHEMBL1026297 | 0.86 | MEN1 (0.44) | MEN1NPC1RAB9AKMT2AEGFR | |
| SCHEMBL13623039 | 0.86 | MEN1 (0.44) | MEN1NPC1RAB9AKMT2AEGFR | |
| SCHEMBL4339317 | 0.85 | EGFR (0.46) | MEN1NPC1RAB9AKMT2AEGFR | |
| SCHEMBL4339321 | 0.85 | EGFR (0.46) | MEN1NPC1RAB9AKMT2AEGFR | |
| SCHEMBL13623042 | 0.83 | BCL6 (0.42) | MEN1NPC1RAB9AKMT2AEGFR | |
| Hydrochloric Acid SCHEMBL1025138 | 0.83 | BCL6 (0.41) | MEN1NPC1RAB9AKMT2AEGFR | |
| Hydrochloric Acid SCHEMBL1025140 | 0.83 | BCL6 (0.41) | MEN1NPC1RAB9AKMT2AEGFR | |
| SCHEMBL4333118 | 0.82 | MEN1 (0.43) | MEN1NPC1RAB9AKMT2AEGFR | |
| SCHEMBL4333125 | 0.82 | MEN1 (0.43) | MEN1NPC1RAB9AKMT2AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | MEN1 1321/4885NPC1 2849/4885RAB9A 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.